These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 911413)

  • 21. Plasma concentration/time curve of erythromycin after a 12-hour intravenous infusion of erythromycin lactobionate in man.
    Parsons RL; David J; Paddock GM; Stamp ST
    Postgrad Med J; 1978 Feb; 54(628):68-71. PubMed ID: 345253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erythromycin serum concentrations following administration in acid-resistant tablets.
    KIRBY WM; MAPLE FM; O'LEARY B
    Antibiot Chemother (Northfield); 1953 May; 3(5):473-7. PubMed ID: 24542409
    [No Abstract]   [Full Text] [Related]  

  • 23. Variations in absorption of erythromycin.
    Lake B; Bell SM
    Med J Aust; 1969 Mar; 1(9):449-51. PubMed ID: 5779053
    [No Abstract]   [Full Text] [Related]  

  • 24. [Effect of acid protective coating on absorption of erythromycin at oral administration].
    Koroleva VG; Belozerova OP; Vasil'ev VK; Stepnaia VE
    Antibiotiki; 1969 Dec; 14(12):1084-8. PubMed ID: 5371175
    [No Abstract]   [Full Text] [Related]  

  • 25. [Influence of ethanol on the in vitro and in vivo drug release from some sustained release tablets (author's transl)].
    Frömming KH; Topaloglu Y
    Arzneimittelforschung; 1975; 25(12):1958-64. PubMed ID: 3188
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antistaphylococcic activity, protective activity in vivo and blood levels in man of triacetyl-oleandomycin and erythromycin].
    Colitti G; Liani M; Stella F
    Antibiotica; 1970; 8(2):216-25. PubMed ID: 5317332
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pharmaceutical studies on commercial phytonadion tablets and effect of polysorbate 80 on the dissolution test (author's transl)].
    Nagata M; Matsuba K; Hasegawa S; Okuda T; Harata M; Hisada K; Ishijima M; Watanabe J
    Yakugaku Zasshi; 1979 Oct; 99(10):965-70. PubMed ID: 544751
    [No Abstract]   [Full Text] [Related]  

  • 28. [Radioactive immunoassay of digoxin during digitalis therapy (author's transl)].
    Gobbi A; Limido A; Chiodini E
    G Ital Cardiol; 1976; 6(2):356-61. PubMed ID: 1010188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The influence of temperature on disintegration and dissolution time of tablets with a cellulose component as a binder (author's transl)].
    Delonca H; Joachim J; Mattha A
    J Pharm Belg; 1978; 33(3):171-8. PubMed ID: 682103
    [No Abstract]   [Full Text] [Related]  

  • 30. [A method for comparison of the dissolution rates in sustained release tablets (author's transl)].
    Gimet R; Milhaud JC; Rabiant J
    J Pharm Belg; 1976; 31(1):89-100. PubMed ID: 1255407
    [No Abstract]   [Full Text] [Related]  

  • 31. [Erythromycin pharmacokinetics in children after rectal and oral administration].
    Nazarov AD; Strachunskiĭ LS; Firsov AA; Petrachenkova NA; Sushkova VI; Sheliakina RD; Kagan EZ; Nesterova LIa; Sinitsyna NI
    Antibiot Khimioter; 1991 Feb; 36(2):36-9. PubMed ID: 2025118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tolerance and effectiveness of oral erythromycin ethyl succinate, intravenous Lactobionate and erythromycin base in infants and small children].
    Krepler P; Steinwenter A
    Arch Kinderheilkd; 1970 Jan; 180(2):129-50. PubMed ID: 5443953
    [No Abstract]   [Full Text] [Related]  

  • 33. [Influency of formation of an hydrophilic and continuous network of starch on tablet properties. 1. Repercussion on disintegration time of tablets and dissolution rate of drug (author's transl)].
    Ringard J; Guyot-Hermann AM
    J Pharm Belg; 1978; 33(2):99-110. PubMed ID: 671212
    [No Abstract]   [Full Text] [Related]  

  • 34. The influence of food on the bioavailability of new formulations of erythromycin stearate and base.
    Rutland J; Berend N; Marlin GE
    Br J Clin Pharmacol; 1979 Oct; 8(4):343-7. PubMed ID: 508509
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Erythromycin in acne vulgaris (author's transl)].
    Hellgren L; Vincent J
    Dermatol Monatsschr; 1981 Apr; 167(4):205-9. PubMed ID: 6455310
    [No Abstract]   [Full Text] [Related]  

  • 36. [Comparative study of the absolute bioavailability of four oral digoxin preparations (author's transl)].
    Rietbrock N; Alken RG; Ebert W
    Arzneimittelforschung; 1979; 29(11):1742-5. PubMed ID: 583489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [On the Polymorphism of barbiturates in powders and tablets. Part 4: the dissolution of barbital B and barbital A (modifications I and III and their release from tablets (author's transl)].
    Hollenbach K; Pintye-Hódi K; Kedvessy G
    Pharmazie; 1980 Jan; 35(1):32-5. PubMed ID: 7384174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Inquiry about the in vitro release of methaqualone from commercial tablet formulations (author's transl)].
    Kerstenne F; Moës A
    J Pharm Belg; 1980; 35(2):150-2. PubMed ID: 7391928
    [No Abstract]   [Full Text] [Related]  

  • 39. Serum levels of flurithromycin ethylsuccinate in healthy volunteers.
    Cocuzza CE; Mattina R; Lanzafame A; Romoli L; Lepore AM
    Chemotherapy; 1994; 40(3):157-60. PubMed ID: 8205933
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Studies on erythromycin stearate capsules (OE-7) (author's transl)].
    Yamashita T; Nishiyama M; Tsubura E
    Jpn J Antibiot; 1976 May; 29(5):552-8. PubMed ID: 933342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.